Reducing medication errors: potential benefits of bolus thrombolytic agents

Area of Science:

• Emergency Medicine
• Cardiology
• Pharmacology

Background:

• Medical errors are prevalent and linked to increased mortality.
• Thrombolytic therapy for acute myocardial infarction (AMI) presents high risks due to time pressure and narrow therapeutic windows.
• Dosing errors in thrombolytic therapy significantly impact patient outcomes, including artery patency, bleeding, and hemorrhage.

Purpose of the Study:

• To evaluate the incidence and impact of medication errors in thrombolytic therapy for AMI.
• To explore the relationship between thrombolytic dosing errors and patient mortality.
• To assess the potential of simpler thrombolytic agents in reducing medication errors.

Main Methods:

• Analysis of data from clinical trials such as GUSTO-I and InTIME2.
• Comparison of medication error rates and associated mortality between different thrombolytic agents and administration methods.
• Review of studies examining the impact of bolus versus infusion thrombolytic administration on error rates.

Main Results:

• The GUSTO-I trial reported significant medication error rates (13.5% for streptokinase, 11.5% for tissue plasminogen activator [t-PA]).
• Thrombolytic dosing errors were associated with significantly higher 30-day mortality rates (e.g., 7.7% for t-PA errors vs. 5.5% for correct t-PA dose).
• More recent studies, including InTIME2, indicate that bolus thrombolytic agents reduce medication error rates.

Conclusions:

• Medication errors, particularly dosing errors, in thrombolytic therapy for AMI are associated with increased mortality.
• The use of simpler, bolus-administered thrombolytic agents shows promise in reducing medication errors in emergency departments.
• Implementing simpler thrombolytic administration strategies may lead to improved clinical outcomes for patients with AMI.